Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the proportion of confirmed responses (complete
response, partial response, and hematologic improvement as defined by revised IWG criteria
during the 12 months of treatment.